Greenwich LifeSciences (GLSI) Ownership - Who owns Greenwich LifeSciences?
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. GLSI showed earnings on May 19, 2025. You can read more about the earnings report here.